Decoy Therapeutics Inc. — Form S-1
Filed July 10, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 78/100
What the filing says
On June 29, 2026, Decoy Therapeutics (pre-clinical biotech, market cap ~$1.9M) closed a $3.5M private placement with one institutional investor (Armistice Capital Master Fund Ltd.), issuing 592,217 pre-funded warrants at $0.0001/share exercise price, 2,961,085 milestone-based warrants at $5.91/share (Series A/B/C tied to clinical milestones), and 213,198 placement agent warrants at $7.3875/share to Curvature Securities. This S-1 registers 3,766,500 resale shares (all warrant-underlying shares). Company has 531,968 common shares outstanding as of June 9, 2026, and substantial doubt regarding going concern—cash sufficient only to late 2026.
Why this rating
Capital raise (~184% of current market cap) is critical for survival but highly dilutive; majority held by single investor; milestone warrants uncertain; heavy reliance on warrant exercise for cash.
Extracted items
- 2.02 results / earnings
- 7.01 Reg FD disclosure
See more from July 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.